相关临床试验
445
119 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1850
进行中（未招募）
28
6.3%
已完成
146
32.8%
No Longer Available
1
0.2%
尚未招募
91
20.4%
招募中
127
28.5%
暂停
1
0.2%
终止
28
6.3%
Unknown
16
3.6%
撤回
7
1.6%
暂无批准数据
- A University of Sydney-led analysis of more than 64,000 middle-aged adults found that varied step counts and walking intensities were each linked to lower mortality risk. - Walking fewer than 5,000 steps daily at a brisk pace of about 80 steps per minute produced mortality reductions comparable to 5,000-7,500 slower steps. - A peak 30-minute cadence of roughly 90-100 steps per minute emerged as a potential target, while 7,500-10,000 daily steps tracked with the lowest mortality risk. - Researchers caution the observational design cannot prove causation, and independent experts note step-intensity evidence remains inconsistent across studies.
- Researchers have demonstrated for the first time that adult human hearts produce new muscle cells after a heart attack, a phenomenon previously documented only in mice. - The finding, published in Circulation Research, relied on a world-first model using heart tissue collected from living patients during bypass surgery. - Cardiovascular disease remains the leading cause of death worldwide, and a heart attack can destroy as many as one third of the cells in the human heart. - The regenerative response is too weak to prevent heart failure, but researchers hope to amplify it to reverse the condition, for which transplant is the only cure.
- Christopher de Clinton Conway of IBRI highlights a New York Times essay arguing that America cannot afford to lose its edge in biotechnology. - Australia has become increasingly attractive for early-stage clinical trials because it moves promising therapies from laboratory to patients faster while maintaining strong safety standards and transparency. - IBRI, the University of Sydney, and the Sydney Biomedical Accelerator are collaborating to connect American and Australian researchers, institutions, and companies. - IBRI President and CEO Alan Palkowitz testified before the U.S. Senate, outlining a national competitiveness strategy to ensure biotech innovations reach patients faster.
- Associate Professor Ines Pires da Silva and her team have expanded one of the world's largest melanoma immunotherapy research cohorts to more than 600 patients, with paired pre- and post-treatment tumour samples. - A new online clinical tool launching this month will predict an individual patient's risk of melanoma recurrence following surgery, using clinical features to generate personalised risk estimates. - The research program focuses on identifying biomarkers that predict immunotherapy response and resistance, with discoveries that could influence treatment across multiple tumour types beyond melanoma. - The team has published nearly 10 scientific papers in the past year and anticipates major publications in 2026 and 2027, with Assoc Prof Pires da Silva taking on leadership roles at ASCO and ESMO.
- A global analysis of over 106,000 pediatric infection samples across 82 countries found antibiotic resistance increased in every region between 2004 and 2022. - Gram-negative bacteria Acinetobacter baumannii and Klebsiella are driving resistance, with carbapenem resistance projected to reach 82% and 35% respectively by 2035. - Babies, children in intensive care, and those in low-resource countries are most affected, with resistance rising fastest to WHO-classified 'Watch' and 'Reserve' antibiotics. - Researchers launched the AMR in Kids platform providing country, pathogen, and antibiotic-class forecasts to 2035 to guide treatment decisions and public health planning.
- The Bulletin of Atomic Scientists included mirror life as a threat for the first time in 2026, moving the Doomsday Clock four seconds closer to midnight to 85 seconds, the closest ever. - Thirty-eight scientists, including two Nobel laureates, called for a research halt in December 2024, with 96 experts from more than 20 countries endorsing a moratorium by April 2025. - Mirror life consists of synthetic organisms built from molecules with reversed chirality that would be invisible to immune systems, posing a potentially irreversible and catastrophic ecological risk. - Some researchers, including Ricard Solé and Andrew Ellington, argue mirror organisms would struggle to compete with natural life, questioning whether a total ban is warranted.
- A meta-analysis of 23 randomized controlled trials involving 2,028 adults found melatonin reduced chronic musculoskeletal pain by approximately 9 points on a 0–100 scale, comparable to opioids, NSAIDs, and paracetamol. - The study highlights melatonin's dual-action mechanism, simultaneously improving sleep quality and reducing pain, breaking the bidirectional cycle of pain-induced sleep disruption and sleep-deprivation-induced hyperalgesia. - Melatonin demonstrated an excellent safety profile with side effects (nausea, dizziness, headaches) occurring at rates similar to placebo and no evidence of dependence or respiratory depression. - Researchers from the University of Sydney emphasize melatonin should serve as an adjunct within comprehensive pain management plans, not as a replacement for existing therapies.
- Professor Robyn Jamieson's team received $200,000 from the NSW Government's NAT-Net scheme to advance lab-grown retina research for inherited blindness over two years. - The project uses non-animal technologies to identify which patients with inherited blindness are most likely to respond to gene therapy, enabling access to previously unavailable treatments. - Two additional grants were awarded for programmable microbeads to grow human tissue and a computer model predicting side effects of medicines for spinal muscular atrophy and Huntington's disease. - The funding is part of a $4.5 million NSW Government investment to reduce animal use in medical research and accelerate human-relevant therapeutic discovery.
- Researchers identified a previously unrecognised lung-specific form of the DPP9 enzyme carrying a genetic variant linked to severe COVID-19 and lung fibrosis. - The variant rs12610495 alters the function of this hidden protein, which had remained overlooked because it is absent from standard reference genome databases. - The study combined large genetic datasets with long-read RNA sequencing and computational modelling across 22 tissues to map disease-associated variants to alternative protein forms. - Findings suggest many disease-linked genetic changes act through previously hidden proteins, opening new opportunities for diagnosis and therapeutic targeting.
- A comprehensive qualitative risk assessment published in *Carcinogenesis* finds that nicotine-based e-cigarettes are likely carcinogenic, with consistent evidence across human biomarker studies, animal models, and mechanistic data. - Researchers report that 22.5% of mice exposed to e-cigarette aerosol developed lung adenocarcinomas, while human studies show DNA damage, oxidative stress, and inflammation linked to vaping. - Dual users of both e-cigarettes and conventional cigarettes face a four-fold increased risk of developing lung cancer, according to recent epidemiological evidence from the USA. - The authors warn against repeating the decades-long delay that occurred before smoking was officially recognized as a cause of lung cancer, urging a precautionary approach now.
